AstraZeneca has been on a sector-beating growth streak since 2018, but this could tail off in the coming years as its biggest earning therapies mature. The company believes it can sustain this performance beyond 2030, based on the planned launch of 15 new molecular entities in the next six years.
Key Takeaways
-
AstraZeneca is on course to achieve double-digit growth from 2021 to 2025, but after that the picture is less certain
Analysts remain skeptical, though, as this forecast relies heavily on unproven early-stage molecules, while its biggest sellers edge towards US...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?